By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Monday that its board has approved a new $200 million stock repurchase program.
The board had previously approved a $100 million stock buyback program in March.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.
Cancer clinical trial patients settle with Anil Potti and Duke University.
A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.
Two Johns Hopkins researchers discuss the need for evidence-based data analysis.